Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 11, 2018updated 28 Oct 2021 1:24pm

Otsuka Medical Devices to merge with ReCor Medical

Japan-based Otsuka Medical Devices, a subsidiary of Otsuka group, and its holding company Otsuka Holdings have entered into a merger agreement with US-based medical device firm ReCor Medical.

Japan-based Otsuka Medical Devices, a subsidiary of Otsuka group, and its holding company Otsuka Holdings have entered into a merger agreement with US-based medical device firm ReCor Medical.

Under the terms of the agreement, which is subject to shareholder approval, Otsuka Holdings will buy the remaining shares in ReCor from French venture capital firm Sofinnova Partners.

ReCor designs and manufactures an ultrasound ablation device called Paradise System for renal denervation (RDN).

“Under the terms of the agreement, which is subject to shareholder approval, Otsuka Holdings will buy the remaining shares in ReCor from French venture capital firm Sofinnova Partners.”

The company obtained the US Food and Drug Administration (FDA) approval last month to evaluate the safety and effectiveness of Paradise Renal Denervation System for decreasing blood pressure in hypertensive patients.

During the previous RADIANCE-HTN SOLO study in subjects with hypertension, the system met the primary efficacy endpoint of statistically significant blood pressure reduction.

Otsuka Holdings president and representative director Tatsuo Higuchi said: “Our decision today reflects not only ReCor’s excellent clinical results but also the close relationship we have built over the years.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

“Our acquisition of ReCor represents an important step forward for Otsuka’s medical device business, leveraging an innovative technology with Otsuka’s expertise in pharmaceuticals and clinical development.”

After the completion of the merger, ReCor will continue developing and assessing the Paradise System in hypertension to support its plans for global commercialisation.

In addition, the system will be investigated for other clinical applications, including heart failure, kidney disease and metabolic conditions.

ReCor Medical president and CEO Andrew Weiss said: “We are excited to move forward in our collaboration with Otsuka to make the Paradise Renal Denervation System a standard of care for treatment of hypertensive patients worldwide.”

ReCor will also help construct Otsuka Medical Devices’ incubation and clinical development hub in the US and Europe.

Related Companies

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU